Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910166 | 1.00 | KCNH2 (0.42) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL909973 | 0.91 | KCNH2 (0.51) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL909971 | 0.91 | KCNH2 (0.51) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL15850845 | 0.91 | KCNH2 (0.51) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL15850841 | 0.87 | KCNH2 (0.44) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL4153118 | 0.80 | CYP1A2 (0.44) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL15850811 | 0.79 | CYP1A2 (0.41) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL15850857 | 0.79 | KCNH2 (0.46) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL15850854 | 0.79 | KCNH2 (0.46) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL910325 | 0.78 | CYP1A2 (0.41) | KCNH2CYP1A2ALDH1A1TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2238138-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009087153-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NRDC, NCL, NPM1 | KCNH2 3726/4885CYP1A2 2854/4885ALDH1A1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.